Accelerating Cancer Therapeutics (ACT)
The Herbert Irving Comprehensive Cancer Center (HICCC) is inviting Columbia University faculty to submit pre-proposal applications for its annual pilot awards. Accelerating Cancer Therapeutics (ACT) is an accelerator program designed to leverage Columbia’s proficiency in drug discovery and provide access to entrepreneurs and the pharmaceutical industry to advance novel cancer therapeutics from the lab towards the path of commercialization and clinical implementation. The program will provide education, mentorship and funding to help academic translational research projects move beyond the “valley of death” in therapeutic development and reach significant milestones. A key goal of this program is to accelerate translation of novel medical discoveries in cancer from the lab to the clinic by positioning the technology for commercialization. Applicants must have a full-time Columbia University faculty appointment. Projects must focus on translating a validated target and address a clear unmet medical need in cancer.
Selected pre-proposal applications will be required to attend a Life Science Accelerator Boot Camp, run in partnership with Irving Institute Translational Therapeutics (TRx) Accelerator and the Columbia Biomedical Technology Accelerator (BiomedX), which consists of interactive evening sessions that will aid in preparation of the full proposal. During the training period, additional resources (business consultants, core facility resources, etc.) can be provided as needed to the project teams. The full proposal will outline the target market and feasible milestones for the one-year development project. Details of the full proposal application requirements and format will be provided at a later date. Pre-proposals are due by 5:00 PM EST on Monday, November 4, 2019.